Table 5.
Dose-response experiments
| MDP |
Frequency |
Amplitude |
dVm/dtmax |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Drug | Parameter | Ref. | E | MS | E | MS | E | MS | E | MS |
| Mibefradil NiCl2 | gCa(T) | (5,16)∗ | NS | Dec | Dec | Dec | Dec | Dec | Dec | Dec |
| BAPTA | μS1S2/μS2Cy | (5,47)† | Inc | NC | Dec | Dec | Dec | Dec | Dec | Dec |
| Low [Ca2+]o | CO | (5)∗ | Dec | Dec | Dec | Dec | Dec | Dec | Dec | Dec |
| Low [Na+]o | NO | (5)∗ | Inc | Inc | Dec | Dec | Dec | Dec | Dec | Dec |
| High [K+]o | KO | (5) | Inc | Inc | Dec | Dec | Dec | Dec | Dec | Dec |
| Norepinephrine phenylephrine | P | (47) | NS | Dec | Inc | Inc | NS | Inc | NS | Inc |
| CGP37157 clonazepam | VNCX‡ | (57) | Inc | NC | Dec | Dec§ | Dec | Dec | Dec | Dec |
| E-4031 | gK(ERG) | (58) | Inc | Inc | Dec | Dec | Inc | Dec | NS | Dec |
E is experimental observation; MS is model simulation; NS is not specified; Inc is increased; Dec is decreased.
∗
Loss of coordinated pacemaker activity.
†
Loss of all pacemaker activity.
‡
Na-Ca exchange pump proteins.
§
Decrease in slow wave frequency but an increase in rate of pacemaker unit discharge.